Skip to main content
. 2020 Jan 31;17(1):e1003034. doi: 10.1371/journal.pmed.1003034

Table 2. Antibiotic prescription and strategy failure.

Analysis and outcome Number/total (percentage) Unadjusted Adjusted
Pre-intervention  Intervention  OR* (95% CI) p-Value OR (95% CI) p-Value
Primary analyses
Intention-to-treat population
    Antibiotic prescription 179/597 (30%) 101/402 (25%) 1.06 (0.61–1.85) 0.84 1.07 (0.57–2.01) 0.75
    Strategy failure 131/572 (23%) 61/381 (16%) 0.56 (0.34–0.93) 0.02 0.53 (0.32–0.88) 0.01
Per-protocol population
    Antibiotic prescription 179/597 (30%) 83/359 (23%) 0.89 (0.5–1.61) 0.71 0.96 (0.49–1.88) 0.92
    Strategy failure 131/572 (23%) 57/340 (17%) 0.60 (0.36–1.00) 0.05 0.56 (0.34–0.93) 0.03
Sensitivity analyses            
Truncated baseline and post-rollout periods§
    Antibiotic prescription 66/276 (24%) 64/279 (23%) 0.81 (0.45–1.46) 0.48 0.71 (0.38–1.32) 0.27
    Strategy failure 58/261 (22%) 46/269 (17%) 0.57 (0.35–0.94) 0.03 0.54 (0.33–0.90) 0.02
Strategy failure, including missing values
    Assumption missing = failure 156/597 (26%) 82/402 (20%) 0.56 (0.36–0.88) 0.01 0.55 (0.35–0.87) 0.01
    Assumption missing = no failure 131/597 (22%) 61/402 (15%) 0.59 (0.36–0.96) 0.03 0.56 (0.34–0.91) 0.02
Secondary analyses            
Compliance (Feverkidstool calculated and patient treated according to advice) NA 359/402 (89%)
Complications 1/572 (0.1%) 1/381 (0.2%)
Strategy failure: reasons    
Secondary antibiotic prescription 45/572 (8%) 29/381 (8%)
Changed antibiotics during follow-up 14/572 (2%) 5/381 (1%)
Secondary hospitalisation** 16/572 (3%) 13/381 (3%)
Oxygen need at day 7 9/572 (2%) 1/381 (0.2%)
Fever at day 7 47/572 (8%) 13/381 (3%)

Bolding indicates statistical significance.

*Main model: clustered by hospital, adjusted for time period. Time-adjusted intracluster correlation coefficient for antibiotic prescription = 0.04, for strategy failure = 0.

p-Values based on multivariable logistic regression.

Adjusted model: main model further adjusted for age, sex, season, ill appearance, and duration of fever.

§Using data from 4 weeks before until 4 weeks after the rollout period, resulting in 9 time periods of equal length, truncating the prolonged baseline and post-rollout periods.

Complications were 1 admission to intensive care unit in the pre-intervention phase and 1 pleural empyema in the intervention phase (both unrelated to study intervention).

**Including 1 admission to the intensive care unit in the pre-intervention group.

NA, not applicable.